Nuclear Medicine

Postal address
Laarbeeklaan 101
1090
Jette
Belgium

Supporting clinical sciences

Postal address
Laarbeeklaan 101
1090
Brussels
Belgium

Expertise

Development of radiopharmaceuticals for PET and radionuclide therapy applications based on camelid single domain antibody fragments (also called VHH or Nanobodies).

Optimization of (automated) radiolabeling procedures, purification methods and formulation. In vitro and in vivo evaluation of new radiopharmaceutical probes in terms of biodistribution, in vivo stability and targeting potential. Translation of preclinically validated tracers to early phase clinical trials, including fulfilling all regulatory requirements.

GMP manufacturing of radiopharmaceuticals.

Research output

  1. Site-specifically radiolabelled human PD-L1 nanobody: A new tool for clinical PET imaging

    Research output: Contribution to journalMeeting abstract (Journal)Research

  2. Combining Bismuth-213 with Nanobodies: Finding the Perfect Match for Targeted Alpha Therapy

    Research output: Chapter in Book/Report/Conference proceedingConference paperResearch

View all (199) »

Activities

  1. Preclinical development with Nanobodies with a focus on ovarian cancer

    Activity: Talk or presentationTalk or presentation at a conference

  2. An 131I-labeled camelid single-domain antibody fragment to treat HER2-overexpressing cancer

    Activity: Talk or presentationTalk or presentation at a conference

  3. Human PD-L1 Nanobody for PET imaging: A site-specific radiolabeling strategy

    Activity: Talk or presentationTalk or presentation at a conference

View all (28) »

ID: 157891